Aromatase inhibitor-associated bone loss: clinical considerations (Q37354121)

19 August 2017

1 reference

title

Aromatase inhibitor-associated bone loss: clinical considerations (English)

1 reference

19 August 2017

Shubham Pant

1

1 reference

PubMed ID

19093701

19 August 2017

Charles L Shapiro

series ordinal

2

1 reference

19 August 2017

1 January 2008

1 reference

19 August 2017

1 reference

19 August 2017

68

1 reference

19 August 2017

18

1 reference

19 August 2017

2591-2600

1 reference

https://scigraph.springernature.com/pub.10.2165/0003495-200868180-00005

19 August 2017

0 references

cites work

Effects of tamoxifen on bone mineral density in postmenopausal women with breast cancer

1 reference

Crossref

https://api.crossref.org/works/10.2165%2F0003495-200868180-00005

Influence of pattern of menopausal transition on the amount of trabecular bone loss. Results from a 6-year prospective longitudinal study.

21 January 2018

1 reference

12 December 2020

Clinical development of anti-RANKL therapy

1 reference

12 December 2020

Osteoprotegerin and RANKL regulate bone resorption, density, geometry and strength

1 reference

12 December 2020

Once-yearly zoledronic acid for treatment of postmenopausal osteoporosis

1 reference

12 December 2020

The hypothalamic control of bone mass, implication for the treatment of osteoporosis.

1 reference

12 December 2020

Zoledronic Acid Prevents Cancer Treatment–Induced Bone Loss in Premenopausal Women Receiving Adjuvant Endocrine Therapy for Hormone-Responsive Breast Cancer: A Report From the Austrian Breast and Colorectal Cancer Study Group

1 reference

12 December 2020

Switching of postmenopausal women with endocrine-responsive early breast cancer to anastrozole after 2 years' adjuvant tamoxifen: combined results of ABCSG trial 8 and ARNO 95 trial

1 reference

12 December 2020

Treatment of established osteoporosis: a systematic review and cost-utility analysis.

1 reference

12 December 2020

Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial

1 reference

12 December 2020

Diagnosis of osteoporosis and assessment of fracture risk

1 reference

12 December 2020

Letrozole. A review of its use in postmenopausal women with advanced breast cancer

1 reference

12 December 2020

Estrogen: effects and actions in osteoporosis

1 reference

12 December 2020

Exercise effects on bone mineral density in women with breast cancer receiving adjuvant chemotherapy

1 reference

12 December 2020

Effect of anastrozole on bone mineral density: 5-year results from the anastrozole, tamoxifen, alone or in combination trial 18233230.

1 reference

12 December 2020

Cancer-treatment-induced bone loss, part 2.

1 reference

12 December 2020

Effects of third-generation aromatase inhibitors on bone

1 reference

12 December 2020

Survival and safety of exemestane versus tamoxifen after 2-3 years' tamoxifen treatment (Intergroup Exemestane Study): a randomised controlled trial

1 reference

12 December 2020

Tolerability of different dosing regimens of bisphosphonates for the treatment of osteoporosis and malignant bone disease.

1 reference

12 December 2020

Aromatase, aromatase inhibitors, and breast cancer

1 reference

12 December 2020

Adjuvant aromatase inhibitors and bone health

1 reference

12 December 2020

Effect of an aromatase inhibitor on bmd and bone turnover markers: 2-year results of the Anastrozole, Tamoxifen, Alone or in Combination (ATAC) trial (18233230)

1 reference

12 December 2020

American Society of Clinical Oncology technology assessment on the use of aromatase inhibitors as adjuvant therapy for postmenopausal women with hormone receptor-positive breast cancer: status report 2004.

1 reference

12 December 2020

Influence of letrozole and anastrozole on total body aromatization and plasma estrogen levels in postmenopausal breast cancer patients evaluated in a randomized, cross-over study

1 reference

12 December 2020

Receptor activator of nuclear factor kappaB ligand and osteoprotegerin regulation of bone remodeling in health and disease.

1 reference

12 December 2020

Current management of treatment-induced bone loss in women with breast cancer treated in the United Kingdom

1 reference

12 December 2020

Promoting health and physical function among cancer survivors: potential for prevention and questions that remain

1 reference

12 December 2020

Adverse effects of bisphosphonates: current issues.

1 reference

12 December 2020

Bone strength: the whole is greater than the sum of its parts

1 reference

12 December 2020

Comparing Therapies for Postmenopausal Osteoporosis Prevention and Treatment

1 reference

12 December 2020

Long-term prevention of postmenopausal osteoporosis by oestrogen. Evidence for an increased bone mass after delayed onset of oestrogen treatment

1 reference

12 December 2020

Bone marrow, cytokines, and bone remodeling. Emerging insights into the pathophysiology of osteoporosis

1 reference

12 December 2020

Effects of exemestane administered for 2 years versus placebo on bone mineral density, bone biomarkers, and plasma lipids in patients with surgically resected early breast cancer

1 reference

12 December 2020

The RANK/RANKL/OPG triad in cancer-induced bone diseases

1 reference

12 December 2020

A review of the literature on osteonecrosis of the jaw in patients with osteoporosis treated with oral bisphosphonates: prevalence, risk factors, and clinical characteristics

1 reference

12 December 2020

Lack of association between oral bisphosphonates and osteonecrosis using jaw surgery as a surrogate marker

1 reference

12 December 2020

Calcium plus vitamin D supplementation and the risk of fractures

1 reference

12 December 2020

Pharmacology and clinical experience with exemestane

1 reference

12 December 2020

Pathogenesis of bone fragility in women and men.

1 reference

12 December 2020

Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates

1 reference

12 December 2020

Chemical castration induced by adjuvant cyclophosphamide, methotrexate, and fluorouracil chemotherapy causes rapid bone loss that is reduced by clodronate: a randomized study in premenopausal breast cancer patients

1 reference

12 December 2020

Mechanisms of action of bisphosphonates: similarities and differences and their potential influence on clinical efficacy.

1 reference

12 December 2020

The bone quality framework: determinants of bone strength and their interrelationships, and implications for osteoporosis management

1 reference

12 December 2020

Anastrozole. A review of its use in the management of postmenopausal women with advanced breast cancer

1 reference

12 December 2020

Osteonecrosis of the jaw in cancer after treatment with bisphosphonates: incidence and risk factors

1 reference

12 December 2020

Fracture prevention with vitamin D supplementation: a meta-analysis of randomized controlled trials

1 reference

12 December 2020

Management of cancer treatment-induced bone loss in early breast and prostate cancer -- a consensus paper of the Belgian Bone Club

1 reference

12 December 2020

American Association of Oral and Maxillofacial Surgeons position paper on bisphosphonate-related osteonecrosis of the jaws

1 reference

12 December 2020

Aromatase inhibitors and bone

1 reference

12 December 2020

Changes in bone mineral density with age in men and women: a longitudinal study

1 reference

12 December 2020

Randomized trial of letrozole following tamoxifen as extended adjuvant therapy in receptor-positive breast cancer: updated findings from NCIC CTG MA.17.

1 reference

12 December 2020

Annual skeletal balance and metabolic bone marker changes in healthy early postmenopausal women: results of a prospective study.

1 reference

12 December 2020

Safety profile of intravenous bisphosphonates

1 reference

12 December 2020

Pharmacokinetic and pharmacologic variation between different estrogen products

1 reference

12 December 2020

Five Years of Letrozole Compared With Tamoxifen As Initial Adjuvant Therapy for Postmenopausal Women With Endocrine-Responsive Early Breast Cancer: Update of Study BIG 1-98

1 reference

12 December 2020

Exemestane: a potent irreversible aromatase inactivator and a promising advance in breast cancer treatment

1 reference

12 December 2020

Postmenopausal hormone replacement therapy: scientific review

1 reference

12 December 2020

2002 clinical practice guidelines for the diagnosis and management of osteoporosis in Canada.

1 reference

12 December 2020

Ovarian failure after adjuvant chemotherapy is associated with rapid bone loss in women with early-stage breast cancer.

1 reference

12 December 2020

Risk factors for hip fracture in white women. Study of Osteoporotic Fractures Research Group.

1 reference

12 December 2020

Cancer treatment-related bone loss: a review and synthesis of the literature

1 reference

12 December 2020

Riding the crest of the teachable moment: promoting long-term health after the diagnosis of cancer

1 reference

12 December 2020

Improving bone health in patients with early breast cancer by adding bisphosphonates to letrozole: the Z-ZO-E-ZO-FAST program

1 reference

12 December 2020

European guidance for the diagnosis and management of osteoporosis in postmenopausal women

1 reference

12 December 2020

The RANKL/RANK/OPG pathway

1 reference

12 December 2020

Osteopenia and osteoporosis in women with breast cancer

1 reference

12 December 2020

Skeletal effects of exemestane on bone-mineral density, bone biomarkers, and fracture incidence in postmenopausal women with early breast cancer participating in the Intergroup Exemestane Study (IES): a randomised controlled study.

1 reference

12 December 2020

Safety of aromatase inhibitors in the adjuvant setting

1 reference

12 December 2020

Pathophysiology of age-related bone loss and osteoporosis

1 reference

12 December 2020

Critical review: updated recommendations for the prevention, diagnosis, and treatment of osteonecrosis of the jaw in cancer patients--May 2006.

1 reference

12 December 2020

Osteoporosis prevention, diagnosis, and therapy

1 reference

12 December 2020

Aromatase inhibitors in breast cancer

1 reference

12 December 2020

Aromatase and its inhibitors: significance for breast cancer therapy

1 reference

12 December 2020

Zoledronic acid inhibits adjuvant letrozole-induced bone loss in postmenopausal women with early breast cancer

1 reference

12 December 2020

Breast cancer tissue estrogens and their manipulation with aromatase inhibitors and inactivators

1 reference

12 December 2020

American Society of Clinical Oncology 2003 update on the role of bisphosphonates and bone health issues in women with breast cancer

1 reference

12 December 2020

A reference standard for the description of osteoporosis

1 reference

12 December 2020

The steroidal aromatase inhibitor exemestane prevents bone loss in ovariectomized rats.

1 reference

12 December 2020

Clinical use of bone densitometry: scientific review

1 reference

12 December 2020

Endocrine effects of aromatase inhibitors and inactivators in vivo: review of data and method limitations

1 reference

12 December 2020

Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: potential implications for the pathogenesis and treatment of malignant bone diseases

1 reference

12 December 2020

Effective inhibition of aromatase inhibitor-associated bone loss by zoledronic acid in postmenopausal women with early breast cancer receiving adjuvant letrozole: ZO-FAST Study results.

1 reference

12 December 2020

Estrogen deficiency and bone loss: an inflammatory tale

1 reference

12 December 2020

Effect of letrozole versus placebo on bone mineral density in women with primary breast cancer completing 5 or more years of adjuvant tamoxifen: a companion study to NCIC CTG MA.17

1 reference

12 December 2020

Minimal levels of serum estradiol prevent postmenopausal bone loss

1 reference

12 December 2020

Progress and promise: highlights of the international expert consensus on the primary therapy of early breast cancer 2007.

1 reference

12 December 2020

10.2165/0003495-200868180-00005

Identifiers

DOI

1 reference

19 August 2017

1 reference

PubMed ID

19093701